Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ).
Hangzhou Tigermed Consulting Co., Ltd. plans to change its registered address to a newly completed self-built building in Binjiang District, Hangzhou, pending approval at a forthcoming general meeting. The company will also seek shareholder approval for amendments to its Articles of Association to align with current PRC company and securities laws and regulatory guidelines, and will authorize the board and management to handle regulatory approvals and wording adjustments, signaling an administrative upgrade that may streamline governance and support its ongoing listed-company obligations.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$61.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-based company listed in Hong Kong, operating in the clinical research and pharmaceutical services industry. It provides contract research and related consulting services to pharmaceutical and biotech clients, supporting drug development and regulatory compliance in both domestic and international markets.
YTD Price Performance: 29.76%
Average Trading Volume: 2,192,942
Technical Sentiment Signal: Buy
Current Market Cap: HK$56.11B
See more insights into 3347 stock on TipRanks’ Stock Analysis page.